DAVID EDWARDS: Open Payments
NPI 1467025981 · CRESTVIEW HILLS, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 29 payments from 10 companies in 2025. Trend: 2023 $557 · 2024 $553 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $239 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Noven Therapeutics, LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: VRAYLAR, INGREZZA, REXULTI, Auvelity, CAPLYTA, Xelstrym, AUSTEDO XR, HETLIOZ.
Industry payments across KY — which companies pay providers there.
